Allogeneic γ9δ2 T Cells Treatment of Recurrent Hematologic Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 3, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Hematologic Diseases
Interventions
BIOLOGICAL

allogeneic γ9δ2 T Cells

dose escalation (3+3) : dose 1 (5 × 10\^7cells/kg) ,dose 2 (1 × 10\^8 cells/kg) ,dose 3 (2 × 10\^8cells/kg)

DRUG

Fludarabine

Intravenous fludarabine on days-5 and -4,the infusion dose is adjusted according to the subject's condition

DRUG

Cyclophosphamide

Intravenous cyclophosphamide on days -5、-4、and -3, the infusion dose is adjusted according to the subject's condition

DRUG

Zoredronic acid

Intravenous zoredronic acid 50ug/kg 24 hours before cell infusion(or according to the dosage of the instruction)(If applicable)

Trial Locations (1)

230036

RECRUITING

Anhui Provincial Hospital, Hefei

All Listed Sponsors
lead

Anhui Provincial Hospital

OTHER_GOV